

Research Activities Newsletter

May/June 2023

In the News: Congratulations to the following awardees!!



Rachael Hageman Blair, Associate Professor of Biostatistics, is Co-I on a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH (PI: Chelsie Elizabeth Armbruster, Microbiology and Immunology) for the research project entitled, *Conserved Proteus Mirabilis Genetic Requirements for Colonization of the Catheterized Urinary Tract*. The study continues to uncover novel, conserved, and clinically relevant targets for therapeutic intervention of catheter-associated urinary tract infections, which are among the most common hospital-acquired infections worldwide.




Katarzyna Kordas, Associate Professor of Epidemiology and Environmental Health, is PI on an administrative supplement from the National Institute of Environmental Health Sciences/NIH for the research project entitled, *Effect of Complex Mixtures on Oxidative Stress and Cognition in Children*. The proposed study will consist of 3 years of follow-up of Salud Ambiental Montevideo (SAM) children in Uruguay to annually characterize the levels of metals in blood and urine, and metabolites of chlorpyrifos, pyrethroids, and polycyclic aromatic hydrocarbons (PAHs) in urine. These children were enrolled between years 2012-19 and currently range in age 7-15 years and have been followed-up for 0-5 years depending on their year of enrollment.



Lucia Leone, Associate Professor of Community Health and Health Behavior, is Co-I on a continuation award (PI: Stephanie Anzman-Frasco, Pediatrics) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development/NIH for the project entitled, *Promoting Healthier Meal Selection and Intake among Children in Restaurants*. Work continues to reach the study goal to establish the effectiveness of an in-restaurant intervention that is easy to implement and can be applied across restaurant contexts to promote healthier eating among children.




Jeffrey Miecznikowski, Interim Chair and Associate Professor of Biostatistics, is Co-I on a new award from the Erie County Medical Center (PI: Patricia Diaz-Moreno, Oral Biology) for the project entitled, *HPV and HIV Coinfection: Clinical-Socio-Behavioral and Microbiome Implications*. This study will determine if there are specific biologic, immunologic or behavioral signatures in people living with HIV (PLWH) co-infected with HPV.



Sue Ann Sisto, Chair and Professor and **Ghazala Saleem**, Assistant Professor both of Rehabilitation Science are Co-PI's on a new REU supplement award from the National Science Foundation (Lead PI: Filip Stefanovic, Biomedical Engineering) for the project entitled, *SEPCORPS Model – SEParating COrtical and SPinal -level Motor Control Responses Using Transcranial Direct Current Stimulation and Transcutaneous Electrical Stimulation*. This study will examine the brain's adaptation in relation to the spinal cords role in modifying movement behavior based on the information it receives from the body's natural sensors. The goal for this project is to develop the first corticospinal model that can capture cortical and spinal-level motor contributions modified by neurostimulation.





Meng Wang, Assistant Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Institute of Environmental Health Sciences/NIH for the research project entitled, *Air Pollution, Coronary events, Atherosclerotic Progression in a Susceptible Population*. The study will continue to examine whether exposure to air pollutants alters coronary biological process, accelerate disease progression, and contributes to coronary heart disease in 3500 patients with atherosclerosis in Beijing. **Jeffrey Miecznikowski**, Interim Chair and Associate Professor of Biostatistics and **Lina Mu**, Associate Professor of Epidemiology and Environmental Health are Co-Investigators.



Gregory Wilding, Professor and former Chair of Biostatistics, is Co-I on three awards. The first is a new award from the National Institute on Alcohol Abuse and Alcoholism/NIH (PI: Braden Linn, School of Social Work) for the project entitled, *Emotion Dynamics and Alcohol Use in NIAAA-defined Recovery from Alcohol Use Disorder*. To better understand the relationship of emotion dynamics and alcohol recovery, this study proposes to recruit individuals in each of the first three recovery categories (e.g., initial, early, and sustained) who have achieved cessation of heavy drinking and remission from a DSM-5 AUD diagnosis and thus meet NIAAA criteria for AUD recovery.

The other two projects are continuation awards. The first is from the National Institute of Allergy and Infectious Diseases/NIH, (PI: Jonathan Lovell, Biomedical Engineering), for the research project entitled, *Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria Vaccine*. The project continues working to develop a vaccine that will block the transmission of malaria by focusing the immune response towards the same target epitope of a potent monoclonal.

The second continuation award is from the National Institute of Aging/NIH (PI: Elsa Bou Ghanem, Microbiology and Immunology) for the project entitled, *The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses*. This project continues to determine the role of polymorphonuclear leukocytes in the age-driven reduction in vaccine responses and increased susceptibility to streptococcus pneumoniae.

In This Issue

In the News: Congratulations to the Following Awardees 1

Grant Clinic 3

NIH Funding Opportunities

Request for Applications (RFA) 5

Program Announcements Reviews in an Institute (PAR).....11

Program Announcements.....16

Robert Wood Johnson Foundation.....16

National Institute on Disability, Independent Living, and Rehabilitation Research.....16

Words to Live By 17

Grant Clinic

GENERAL NOTICE

[NOT-HL-23-088](#)

Updated Notice of Information for HIV research priorities at the National Heart, Lung, and Blood Institute

The purpose of this Notice is to inform the scientific community of HIV-focused research priorities that are of interest to the National Heart, Lung, and Blood Institute (NHLBI). NHLBI supports research on HIV-associated heart, lung, blood and sleep (HLBS) comorbidities, coinfections, and complications, including ancillary studies using established cohorts and repository data and specimens, in all people regardless of age, sex, gender identity, sexual orientation, race, ethnicity, religion, disability, geographic location, or socioeconomic circumstance, especially people who are both aging and are HIV-infected. NHLBI also supports a range of cross-cutting implementation research as well as basic and health disparities research, and training.

[NOT-AA-23-008](#)

Request for Information on Religion, Spirituality, and Alcohol Research Aims

NIAAA is requesting information from the broad community of alcohol researchers, clinicians, community leaders (including faith leaders), and advocates to help identify the most important research questions surrounding the influence of religion and spirituality on the prevention and treatment of and recovery from alcohol use disorder (AUD) and other co-morbidities. Responses are voluntary and must be received by **August 1, 2023**.

NOTICE OF INTENT TO PUBLISH

[NOT-AA-23-009](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Specialized Alcohol Research Centers (P50 Clinical Trial Optional)

The NIAAA intends to reissue [RFA-AA-22-001](#), Specialized Alcohol Research Centers for applications to develop a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on alcohol misuse and alcohol-related problems, including alcohol use disorder and other health consequences, across the lifespan. The RFA is expected to be published in Spring 2023 with an expected application due date in Fall 2023.

[NOT-AA-23-010](#)

Notice of intent to Publish a Funding Opportunity Announcement for Comprehensive Alcohol Research Centers (P60 Clinical Trial Optional)

The NIAAA intends to promote a new initiative by publishing a RFA to solicit applications to develop a broad-based Comprehensive Alcohol Research Center program to foster and conduct interdisciplinary, collaborative research on alcoholism, alcohol use disorder and the impact of alcohol on health and disease. The RFA is expected to be published in May 2023 with an expected application due date in Fall 2023.

[NOT-AG-23-006](#)

Notice of Intent to Publish a Notice of Funding Opportunity for “Leveraging Social Networks to Promote Widespread Individual Behavior Change (R01 Clinical Trial Optional)

This Notice informs the research community that the National Institute on Aging (NIA) and the National Cancer Institute (NCI) intend to issue a RFA for new applications proposing basic observational or experimental behavioral and/or social science research projects that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. Research supported through this RFA will examine at least two levels of analysis: interpersonal processes and social network characteristics. The RFA is expected to be published in Summer 2023, with an application due date in Fall 2023.

[NOT-AG-23-007](#)

Notice of Intent to Publish a Notice of Funding Opportunity for “Leveraging Social Networks to

Promote Widespread Individual Behavior Change (R34 Clinical Trial Optional)

This Notice informs the research community that the National Institute on Aging (NIA) and the National Cancer Institute (NCI) intend to issue a RFA for new applications proposing projects that support the planning activities necessary to develop social network interventions to promote health across the lifespan, especially in populations in which such interventions are currently largely underdeveloped and untested (such as populations in mid- and late life). Applications will focus on planning activities for social network interventions for which a target interpersonal process of behavior change or social network characteristic has already been identified. The RFA is expected to be published in Summer 2023, with an application due date in Fall 2023.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-MD-23-008](#) – Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities

The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts. This notice applies to due dates on or after **May 17, 2023**, and subsequent receipt dates through **June 5, 2026**.

[NOT-AG-23-027](#) – Small Research Grants for innovations in Health Longevity Research

This Notice invites applications for small research grants that align with the goals of the National Academy of Medicine's [Healthy Longevity Grand Challenge](#), as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This notice applies to due dates on or after **July 16, 2023**, and subsequent receipt dates through **May 7, 2024**.

[NOT-HL-23-089](#) – Research on barriers to care and risk of HIV-associated comorbidities among vulnerable population groups

The purpose of this Notice is to inform potential applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in supporting analysis of barriers to care and risk of HIV-associated comorbidities among disproportionately vulnerable and affected population groups of people living with or at risk for HIV infection. This Notice replaces the former [NOT-HL-22-010](#). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **May 8, 2025**.

[NOT-MH-23-250](#) – Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults

The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications that include developmentally tailored research focused on adolescents and young adults (youth) related to HIV prevention and treatment. This Notice of Special Interest is a reissue of [NOT-MH-20-035](#). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **September 7, 2026**.

[NOT-MH-23-275](#) – Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets

The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving implementation research grant applications designed in partnership with domestic and global service providers to advance HIV prevention and treatment goals (domestically) or targets (globally). This NOSI is a reissue of [NOT-MH-20-024](#). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **September 7, 2026**.

[NOT-CA-23-070](#) – **Research on HIV-associated Malignancies**

This is a continuation of NOT-CA-20-022, "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers, which expired on January 8, 2023. Through this NOSI, the National Cancer Institute (NCI) intends to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), which are now a leading cause of death in people with HIV (PWH). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **September 7, 2026**.

[NOT-MH-23-270](#) – **Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment**

The purpose of this Notice is to call for research to understand and address the impact of HIV-related intersectional stigma and discrimination (ISD), or other social and structural determinants of health (SSDOH) as they relate to HIV prevention and treatment. This NOSI is a reissue of [NOT-MH-20-020](#).

[NOT-MH-23-265](#) – **Mental Health Comorbidities in HIV Prevention and Treatment**

The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. This NOSI is a reissue of [NOT-MH-20-013](#).

POLICY NOTICES

[NOT-HS-23-013](#) – **Special Emphasis Notice: AHRQ Announces Interest in Health Services Research to Advance Health and Healthcare Equity**

The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality's (AHRQ) strong and continued interest in receiving applications that advance the goal of achieving equity in healthcare delivery in the United States. This SEN supersedes the [NOT-HS-21-014](#).

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

AUGUST 2023 DUE DATES

[RFA-MD-23-011](#) – (P50 Clinical Trial Optional)

NIMHD Centers of Excellence in Investigator Development and Community Engagement

This funding opportunity seeks to facilitate the education of participants from diverse backgrounds, including those underrepresented in biomedical research to pursue clinical research, translational and/or patient-oriented research, particularly on diseases that disproportionately impact populations that experience health disparities. **Application Due Date:** August 4, 2023; **Expiration Date:** August 5, 2023.

[RFA-MD-23-004](#) – (R01 – Clinical Trial Optional)

Community Level Interventions to Improve Minority Health and Reduce Health Disparities

This opportunity will support research projects to develop and test prospective community-level interventions to improve minority health and decrease health disparities. The initiative will emphasize research priorities that can be addressed through community-engaged research approaches and that utilize the [NIMHD Research Framework](#) to assess and intervene on health determinants beyond the individual level, at the interpersonal, family, organizational, neighborhood, community, and societal levels. **Application Due Dates:** August 9, 2023; **Expiration Date:** August 10, 2023.

[RFA-DA-24-008](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-009](#) – (R21 Clinical Trials Not Allowed)

Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder

The purpose of this FOA is to encourage research using data science and computational approaches to generate new insights into mechanisms and consequences of the interaction of HIV and addictive drugs. **Letter of Intent Due Date** – July 10, 2023; **Application Due Date:** August 10, 2023; **Expiration Date:** August

11, 2023.

[RFA-DA-24-015](#) – (R61/R33 Clinical Trial Required)

Ending the HIV Epidemic: Focus on Justice Populations with SUD

Under the Ending the HIV Epidemic (EHE) initiative, NIDA is releasing a set of interrelated RFAs to create the HIV/Justice Research Network, a coordinated effort to develop innovative strategies to promote improvements in HIV prevention and treatment services for individuals involved in the criminal legal system with substance use disorder (SUD). This NOFO seeks applications for multiple Regional Research Hubs. These phased awards will partner with the criminal legal system and HIV/SUD service providers in three or more communities to field pilot studies and hybrid implementation-effectiveness trials testing innovative service delivery models to better engage populations involved in the criminal legal system in HIV and SUD prevention, treatment, recovery, and harm reduction. Two interrelated Notices follow below (Data Coordination and Dissemination Center - DCDC; [RFA-DA-24-023](#); Patient Engagement Resource Center PERC; [RFA-DA-24-022](#)). **Application Due Date:** August 16, 2023; **Expiration Date:** August 17, 2023.

[RFA-DA-24-022](#) – (U24 Clinical Trial Optional)

Ending the HIV Epidemic: Resource Center to Engage Justice-Involved Populations

This NOFO seeks applications for an HIV/Justice Patient Engagement Resource Center (PERC). This U24 research resource center will partner with patients and others having lived experience with HIV, SUD, and the criminal-legal system to develop a research advisory/consultation model that can support the Regional Research Hub projects; conduct original research to identify key access and utilization barriers to HIV/SUD services for individuals with criminal-legal involvement; and pilot test potential solutions. **Application Due Date:** August 16, 2023; **Expiration Date:** August 17, 2023.

[RFA-DA-24-023](#) – 9UM1 Clinical Trial Optional)

Ending the HIV Epidemic: Focus on Justice Populations with SUD-Data Coordination and Dissemination Center

This NOFO seeks applications for a Data Coordination and Dissemination Center (DCDC). The DCDC will provide broad coordination and infrastructure support for RRHs funded under RFA-DA-24-015. The DCDC will also work closely with the PERC to engage key stakeholders in network activities. Key responsibilities include administrative and logistical support; data and analytic support; dissemination and stakeholder engagement support; as well as targeted research projects to support the overall work of the network. **Application Due Date:** August 16, 2023; **Expiration Date:** August 17, 2023.

[RFA-RM-23-005](#) – (DP2 clinical Trial Optional)

NIH Director's New Innovator Award Program

The NIH Director's New Innovator Award Program supports early-stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications are sought which reflect the full diversity of the research workforce. **Application Due Date:** August 18, 2023; **Expiration Date:** August 19, 2023.

[RFA-AI-23-032](#) – (U24 Clinical Trials Not Allowed)

Bioinformatics Resource Centers (BRCs) for Infectious Diseases

The purpose of this NOFO is to solicit applications for the Bioinformatics Resource Center (BRC) Program that will address bioinformatics needs in the research community to accelerate the development of diagnosis, prevention, and treatment of infectious diseases. **Application Due Date:** August 25, 2023; **Expiration Date:** August 26, 2023.

SEPTEMBER 2023 DUE DATES

[RFA-RM-23-006](#) – (R01 Clinical Trial Optional)

NIH Director's Transformative Research Awards

The NIH Director's Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. **Application Due Date:** September 1, 2023; **Expiration Date:** September 2, 2023.

[RFA-RM-23-007](#) – (DP5 Clinical Trial)

NIH Director's Early Independence Awards

The NIH Director's Early Independence Award supports rigorous and promising junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. **Application Due Date:** September 6, 2023; **Expiration Date:** September 7, 2023.

[RFA-RM-23-004](#) – (DP1 Clinical Trial Optional)

NIH Director's Pioneer Award Program

The [NIH Director's Pioneer Award Program](#) supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications are sought which reflect the full diversity of the nation's research workforce. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere. **Application Due Date:** September 8, 2023; **Expiration Date:** September 9, 2023.

[RFA-AG-24-037](#) – (U01 Clinical Trial Not Allowed)

Limited Competition: national Health and Aging Trends (NHATS) and National Study of Caregiving (NSOC)

The purpose of this limited competition notice of funding opportunity (NOFO) is to continue data collection, development, and dissemination of the [National Health and Aging Trends Study \(NHATS\)](#) and the [National Study of Caregiving \(NSOC\)](#). This NOFO is limited to investigators and institutions with access to the NHATS and NSOC sample frames, as the frames will be used to contact and collect new data from participants.

Application Due Date: September 29, 2023; **Expiration Date:** September 30, 2023.

OCTOBER 2023 DUE DATES

[RFA-CA-24-005](#) – (U01 Clinical Trial Optional)

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health

This NOFO supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the NOFO solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. **Application Due Date:** October 13, 2023; **Expiration Date:** October 14, 2023.

NOVEMBER 2023 DUE DATES

[RFA-DA-24-016](#) – (R01 R24 Clinical Trial Optional)

Patient Engagement Resource Centers to Inform SUD Treatment Services Research

This Notice invites applications to provide research resource support to the addiction services research community through the creation of Patient Engagement Resource Centers (PERCs). The goal of each PERC is to effectively engage patients (including prospective patients, families of individuals with substance use disorder [SUD], and persons in recovery) in meaningful dialogue to inform the design and interpretation of research trials and treatment services that reflect patients' needs, preferences and priorities. **Application Due Date:** November 2, 2023; **Expiration Date:** November 3, 2023.

[RFA-AG-24-025](#) – (R01 Clinical Trial Optional)

Leveraging Social Networks to Promote Widespread Individual Behavior Change

This Notice is to invite basic observational or experimental behavioral and/or social science applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. **Application Due Date:** November 3, 2023; **Expiration Date:** November 4, 2023.

[RFA-AG-24-026](#) – (R34 Clinical Trial Optional)

Leveraging Social Networks to Promote Widespread Individual Behavior Change

This NOFO invites applications to support the planning activities necessary to develop social network interventions to promote health across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (such as populations in mid- and late-life). **Application Due Date:** November 3, 2023; **Expiration Date:** November 4, 2023.

[RFA-ES-23-007](#) – (P20 Clinical Trial Optional)

Exploratory Grants for Climate Change and Health Research Center Development

The purpose of this NOFO is to solicit planning grant applications for Climate Change and Health Research Centers (CCHRCs). This program will support the development of an innovative research environment to foster and sustain a transdisciplinary program of fundamental and applied research to explore the complex impacts of climate change on health and to develop action-oriented strategies that protect health and build resiliency at the individual, community, national and global levels. **Application Due Date:** November 7, 2023; **Expiration Date:** November 8, 2023.

[RFA-DA-24-019](#) – (R34 Clinical Trial Not Allowed)

Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA)

The goal of this Funding Opportunity is to seek applications proposing a set of planning activities that will lay the groundwork for scientific projects aimed at using animal models and longitudinal research designs to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the risk for substance use disorders (SUD) and their comorbidities in adolescence and adulthood. **Application Due Date:** November 9, 2023; **Expiration Date:** November 10, 2023.

[RFA-DA-24-020](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-021](#) – (R01 Basic Experimental Studies with Humans Required)

Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders

The purpose of this NOFO is to support research project applications to expand our knowledge on the basic neurobiology of the interrelationship between sleep/circadian rhythms and substance use disorders (SUDs). These studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythms and vice-versa and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. **Application Due Date:** November 13, 2023; **Expiration Date:** November 14, 2023.

[RFA-AA-23-001](#) – (P50 Clinical Trial Optional)

Specialized Alcohol Research Centers

The NIAAA supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan. Topics include, but are not limited to, the nature, etiology, genetics, diagnosis, treatment, and prevention of AUD, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and minority health and NIH-designated populations that experience health disparities. **Application Due Date:** November 15, 2023; **Expiration Date:** November 16, 2023.

[RFA-AA-23-002](#) – (P60 Clinical Trial Optional)

Comprehensive Alcohol Research Centers

This Notice invites applications for Comprehensive Alcohol Research Centers which requires a dissemination core to initiate and expand community education related to the activities of the center. The purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, epigenetics, diagnosis, epidemiology, treatment, and prevention of alcohol misuse, alcohol use disorder, alcohol-related end organ diseases and their biomedical, neurochemical, behavioral, psychosocial, and economic consequences across the lifespan and impacting racial and ethnic minority groups and other NIH-designated populations that experience health disparities. **Application Due Date:** November 15, 2023; **Expiration Date:** November 16, 2023.

[RFA-CA-23-014](#) – (R21 Clinical Trial Optional)

Development of Innovation Informatics Methods and Algorithms for Cancer Research and Management

The importance of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation and that have the potential to accelerate or enhance cancer research by inviting Exploratory/Developmental Research grant applications for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum.

Application Due Date: November 17, 2023; **Expiration Date:** November 18, 2023

[RFA-CA-23-015](#)– (U01 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on early-stage development, defined here as initial tool development or the significant modification of an existing tool for a new cancer research application. The FOA encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research.

Application Due Date: November 17, 2023; **Expiration Date:** November 18, 2023

[RFA-CA-23-016](#) – (U24 Clinical Trial Optional)

Advanced Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. **Application Due Date:** November 17, 2023; **Expiration Date:** November 18, 2023

[RFA-CA-23-017](#) – (U24 Clinical Trial Optional)

Sustained Support for Informatics Technologies for Cancer Research and Management

This Announcement is to invite Cooperative Agreement applications for the continued development and sustainment of high-value informatics research resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Date:** November 17, 2023

2024 DUE DATES

[RFA-CA-22-050](#) – (R01 Clinical Trial Optional)

NCI Cancer Moonshot Scholars Diversity Program (CMSDP)

The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups ([NOT-OD-20-031, Notice of NIH's Interest in Diversity](#)), are encouraged to work with their institutions to apply. **Application Due Date:** February 6, 2024; **Expiration Date:** February 7, 2024

[RFA-OD-23-013](#) – (R21 Clinical Trial Optional)

[RFA-OD-23-014](#) – (R01 Clinical Trial Optional)

Understanding Chronic Conditions Understudied Among Women

The purpose of this Funding Opportunity is to invite R21 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the [2019-2023 Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women." **Application Due Date:** June 20, 2024; **Expiration Date:** June 21, 2024

MULTIPLE DUE DATES

[RFA-DA-24-037](#) – (R21 Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

The purpose of this announcement is to invite applications proposing innovative analysis of existing social

science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance use behaviors and related disorders, prevention of substance use and HIV, and health service utilization. **Application Due Dates:** August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; and November 15, 2024

[RFA-OD-23-017](#) – (R01 Clinical Trial Optional)

Tobacco Regulatory Science

This Notice is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Projects must address the research priorities related to the regulatory authority of the FDA Center for Tobacco Products (CTP). **Application Due Dates:** October 6, 2023, May 6, 2024, October 4, 2024, May 2, 2025

[RFA-HG-23-017](#) – (R01 Clinical Trial Optional)

[RFA-HG-23-018](#) – (R21 Clinical Trial Optional)

Investigator-Initiated Research in Genomics and Health Equity

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. **Application Due Dates:** November 8, 2023, July 8, 2024, July 8, 2025

[RFA-OD-22-023](#) – (K01 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-024](#) – (K01 – Independent Clinical Trial Required)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research is to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Application Due Dates:** November 14, 2023, July 12, 2024, March 12, 2025

[RFA-OD-22-025](#) – (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-026](#) – (K99/R00 – Independent Clinical Trial Required)

Pathway to Independence Award in Tobacco Regulatory Research

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. **Application Due Dates:** November 14, 2023, July 12, 2024, March 12, 2025

[RFA-DA-23-013](#) – (R01 Clinical Trial Optional)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to substance use, addiction, and related health outcomes consequences, including HIV. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-061](#) – (R01 Clinical Trial Optional)

[RFA-DA-23-062](#) – (R34 Clinical Trial Optional)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

The purpose of this FOA is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-026](#) – (DP1 Clinical Trial Optional)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make

exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. **Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-028](#) – (R61/R33 Clinical Trial Optional)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-OD-22-028](#) – (R01 Clinical Trial Optional)

The Intersection of Sex and Gender Influences on Health and Disease

The purpose of this FOA is to invite applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#). **Application Due Dates:** November 22, 2023, November 22, 2024

[RFA-NS-22-022](#) – (K99/R00 Independent Clinical Trial Not Allowed)

[RFA-NS-22-023](#) – (Independent Basis Experimental Studies with Humans Required)

HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAID and SUD Research

The purpose of this Announcement is to assist eligible postdoctoral researchers in research areas supported by the NIH HEAL Initiative®, with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025

[RFA-NS-22-024](#) – (K99/R00 Independent Basic Experimental Studies with Humans Required)

[RFA-NS-22-025](#) – (K99/R00 Independent Clinical Trial Not Allowed)

HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity

The purpose of this FOA is to assist a cohort of new and talented independent investigators from diverse backgrounds (e.g. see [NOT-OD-20-031](#) Notice of NIH's Interest in Diversity) with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025

[RFA-ES-23-004](#) – (R21 Clinical Trial Not Allowed)

Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA is intended to support research in environmental health science in which an event has or will imminently occur that provides a limited window of opportunity to collect samples and data to support the assessment of exposures and human health impact. **Due Dates:** Multiple Dates; see announcement. **Expires:** Dec. 2, 2025

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

AUGUST 2023 DUE DATES

[PAR-23-156](#) – (Si2/R00 Clinical Trial Optional)

Lasker Clinical Research Scholars Program

This NOFO encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program combines a period of research experience as a tenure-track Investigator in the IRP with additional years of independent financial support, either within the IRP or at an extramural research institution. **Application Due Date:** August 25, 2023; **Expiration Date:** August 26, 2023

OCTOBER 2023 DUE DATES

[PAR-23-182](#) – (U01 Clinical Trial Not Allowed)

Accelerating Behavioral and Social Science through Ontology Development and Use: Research Network Projects

This Notice invites applications to support research projects focused on the expansion of existing or development of new ontologies for behavioral or social science research (BSSR). The research projects must include multi-disciplinary teams of subject matter experts in one or more BSSR fields, as well as ontology related informatics and computational approaches. **Application Due Date:** October 3, 2023; **Expiration Date:** October 4, 2023

[PAR-23-174](#) – (R36 Clinical Trial Not Allowed)

Aging Research Dissertation Awards to Promote Diversity

This NOFO invites R36 applications to promote diversity in the scientific research workforce engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within [NIA's strategic priorities](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 17, 2024

[PAR-23-083](#) – (R61 Clinical Trial Optional)

Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline

This FOA invites research grant applications that enable the collection of *pilot data* to support early stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. The goal of these pilot data is to serve as preliminary data for applications to the early stage and late stage clinical trial [PAR-23-081](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 19, 2024

[PAR-23-081](#) – (R01 Clinical Trial Optional)

Early and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline

This FOA invites research grant applications that enable the early- to late-stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2025

[PAR-23-177](#) – (R21 Clinical Trials Not Allowed)

Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS)

This opportunity aims to facilitate early-stage technology development that is cutting-edge with transformative potential but for which it may be difficult to secure funding. The opportunity supports early technology development projects that have a strong rationale and conceptual framework but are at the first stages where there are little to no preliminary data. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** June 20, 2025

[PAR-23-116](#) – (P30 Clinical Trial Not Allowed)

Centers for AIDS Research

The purpose of this FOA is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-117](#) – (P30 Clinical Trial Not Allowed)

Developmental Centers for AIDS Research

The FOA is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-269](#) – (DP1 Clinical Trial Optional)

NIDA Avant-Garde Program for IV and Substance Use Disorder Research

Applications responding to this FOA must propose projects that align with the high priority HIV/AIDS research areas as described in [NOT-OD-20-018](#). Areas of interest include innovative basic, clinical or translational research that may lead to improved preventive interventions or therapies; creative strategies to prevent HIV transmission; novel approaches to improve outcomes of HIV and HIV-related comorbidities; innovative ideas to improve health outcomes of people with SUD and are living with HIV; and cutting-edge approaches to eradicating HIV. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 15, 2025

[PAR-23-125](#) – (DP2 Clinical Trial Optional)

Avenir Award Program for Research on Substance Use Disorders and HIV

This Avenir program looks towards the future by supporting early stage investigators (ESI) proposing highly innovative studies at the nexus of substance use disorders (SUD) and HIV. This FOA aims to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV. **Due Dates:** Multiple Dates; see announcement. **Expires:** August 16, 2025

[PAR-23-055](#) – (R01 Clinical Trial Not Allowed)

[PAR-23-056](#) – (R21 Clinical Trial Not Allowed)

Co-infection and Cancer

This FOA is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** R01 – October 5, 2025; R21 – October 16, 2025

[PAR-23-072](#) – (R13 Clinical Trial Not Allowed)

FDA Support for Conferences and Scientific Meetings

The purpose of the FDA Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. *A LOI requesting advanced permission to submit a conference application is required and must be received via e-mail no later than eight (8) weeks prior to the selected application due date.* **Due Dates:** Multiple Dates; see announcement. **Expires:** October 11, 2025

[PAR-23-051](#) – (U01 Clinical Trial Not Allowed)

[PAR-23-052](#) – (UH2 Clinical Trial Not Allowed)

Mechanistic Links between Diet, Lipid Metabolism, and Tumor Growth and Progression

This announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 24, 2025

[PAR-23-076](#) – (P50 Clinical Trial Optional)

NIDA Research Center of Excellence Grant Program

This FOA is to provide support for research Centers that (1) conduct substance use and addiction research in any area of NIDA's mission, including the intersection of substance use/addiction and HIV, (2) foster outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to relevant research communities, educational organizations, the general public, and policy makers. **Application Due Dates:** Multiple dates; see announcement. **Expiration Date:** November 19, 2025

[PAR-23-053](#) – (R61/R33 Clinical Trial Optional)

Research Infrastructure Development for Interdisciplinary Aging Studies

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. Applications should

propose the development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 3, 2025

[PAR-23-191](#) – (R21 Clinical Trial Optional)

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions

This Notice, issued by the Fogarty International Center (FIC), seeks to stimulate innovative ideas and impactful research to better understand the complexities around developing, testing and implementing appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for HIV-associated non-communicable diseases (NCDs) in Low and Middle-Income Countries (LMICs). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 9, 2025

[PAR-23-190](#) – (R01 Clinical Trial Optional)

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries

This NOFO issued by the Fogarty International Center (FIC) seeks to support research to develop and pilot test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The NOFO will also support interventions to address the multiple intersecting stigmas due to co-occurring diseases and/or conditions faced by PLWH. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 23, 2025

[PAR-23-058](#) – (R03 Clinical Trial Optional)

NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus)

This funding opportunity supports small research projects on cancer that can be carried out in a short period of time with limited resources. This grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-034](#) – (R01 Clinical Trial Optional)

NLM Research Grants in Biomedical Informatics and Data Science

This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-036](#) – (R21 Clinical Trial Not Allowed)

Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders

This FOA encourages applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-057](#) – (R01 Clinical Trial Required)

NIA Multi-site Clinical Trial Implementation Grant

This FOA invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the [NIA website](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-064](#) – (P01 Clinical Trial Optional)

NIDA Program Project Grant Applications

NIDA seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, medications development, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted

infections) and associated consequences in people who use or misuse substances or have a substance use disorder, or other research areas relevant to substance use, misuse, or use disorders. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-112](#) – (R01 – Clinical Trial Optional)

Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities

This initiative will support intervention research that addresses structural racism and discrimination (SRD) to improve minority health or reduce health disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-060](#) – (R34 Clinical Trial Optional)

Formative and Pilot Intervention research to Optimize HIV Prevention and Care Continuum Outcomes

[PAR-23-061](#) – (R21 Clinical Trial Optional)

[PAR-23-062](#) – (R01 Clinical Trial Optional)

Innovations to Optimize HIV Prevention and Care Continuum Outcomes

The NIMH invites applications for Research Project Grants that propose formative research, intervention development, and pilot-testing of interventions; formative implementation research to inform adaptation of evidence-based interventions; or development or selection of implementation strategies. Primary scientific areas of focus include the feasibility, acceptability, and safety of novel or adapted interventions that target HIV prevention or treatment, or implementation outcomes using implementation science approaches. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials or implementation science approaches should consider using the companion R01 mechanism, [PAR-23-062](#). If proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models, applications should consider the R21 mechanism ([PAR-23-061](#)). **Application Due Dates:** Multiple Dates; see announcement. **Expires:** January 10, 2026

[PAR-23-077](#) – (RM1 – Clinical Trial Optional)

Collaborative Program Grant for Multidisciplinary Teams

This Announcement encourages Collaborative Program Grant applications from institutions/organizations that propose projects addressing complex and challenging biomedical problems within the mission of NIGMS. **Application Due Dates:** Multiple Dates, see announcement. **Expiration Date:** January 28, 2026

[PAR-23-037](#) – (U01 Clinical Trial Optional)

Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities

The purpose of this FOA is to invite applications for multisite clinical trials and large scale observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice [NOT-HD-19-034](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-111](#) – (R21 – Clinical Trial Optional)

NIMHD Exploratory/Developmental Research Grant Program

NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-122](#) – (R01 Clinical Trial Optional)

Research With Activities Related to Diversity (ReWARD)

The goal of the NIH ReWARD program is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-152](#) – (R21 Clinical Trial Optional)

[PAR-23-153](#) – (R01 Clinical Trial Optional)

Impacts of Climate Change across the Cancer Control Continuum

This Notice aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-155](#) – (R01 Clinical Trial Required)

Understanding Expectancies in Cancer Symptom Management

This NOFO is intended to support mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAS-23-172](#) – (R34 Clinical Trials Optional)

[PAS-23-173](#) – (R01 Clinical Trials Optional)

HIV Prevention and Alcohol

The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-170](#) – (R01 Clinical Trial Required)

Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities

This Notice invites applications to test cancer preventive or screening interventions to reduce the burden of cancer in populations that experience health disparities. The Office of Disease Prevention (ODP) and participating NIH Institutes, Centers, and Offices (ICs) are issuing this to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2027

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-23-196](#)

AHRQ Health Services Research Dissertation Program (R36)

Due Dates: February 1, May 1, August 1, and November 1 annually, beginning August 1, 2023, by 5:00 PM local time of applicant organization.

Expiration Date: May 7, 2028

Robert Wood Johnson Foundation (RWJF) Funding Opportunities

The following opportunities are accepting applications on a rolling basis.

[Evidence for Action: Innovative Research to Advance Racial Equity](#)

Evidence for Action (E4A) prioritizes research to evaluate specific interventions (e.g., policies, programs, practices) that have the potential to counteract the harms of structural and systemic racism and improve health, well-being, and equity outcomes. This funding is geared toward studies about “upstream” causes of health inequities, such as the systems, structures, laws, policies, norms, and practices that determine the distribution of resources and opportunities, which in turn influence individuals’ options and behaviors.

[Pioneering Ideas: Exploring the Future to Build a Culture of Health](#)

This funding opportunity seeks proposals primed to impact health equity moving forward. Robert Wood Johnson Foundation is interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.



National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) Funding Opportunities

[HHS-2023-ACL-NIDILRR](#)

Improving Methods for Conducting Research with People with Cognitive Disabilities in Virtual Environments

Under this DRRP, the grantee must conduct research toward the development of rigorous research methods and approaches that can be used in virtual environments to enable people with cognitive disabilities to share valid, reliable, and meaningful data about their experiences and outcomes. People with cognitive disabilities may include but are not limited to those with intellectual or developmental disabilities, serious mental illness, traumatic brain injury, dementia, or stroke. **Application Due Date:** July 3, 2023

[HHS-2023-ACL-NIDILRR](#)

Promoting Positive Employment Outcomes Among People with Disabilities who are Experiencing Long-COVID

Grantees applying to the DRRP must conduct research toward the development or development and testing of interventions, supports, or accommodations that allow people with disabilities to manage or address Long COVID symptoms to maintain good health and employment. **Application Due Date:** July 10, 2023

Words to Live By

"The meaning of life is to give life meaning." – Ken Hudgins

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras